HaemaLogiX's CSO, Dr. Rosanne Dunn, presents at Cell and Gene Therapy World Asia, Singapore
16 October 2023
HaemaLogix Chief Scientific Officer, Dr. Rosanne Dunn, was invited to present at Cell and Gene Therapy World Asia, held on 14-15 September in Singapore.
Dr. Dunn spoke on the specificity of KMA.CAR-T cells against a novel B cell target called kappa myeloma antigen (KMA), drawing on recent preclinical in vivo studies and clinically proven safety data on our other immunotherapy assets.
KMA.CAR-T, which is being developed by HaemaLogiX in collaboration with the Peter MacCallum Cancer Centre, is ready to enter a phase I clinical trial for patients with myeloma.
HaemaLogiX was one of the few Australian companies represented this year at the conference, which bought together global leaders, visionaries, and pioneers in the field of cell and gene therapy. The conference had a key focus on current best research and development practices, and companies advancing towards manufacturing and commercialisation.
View the presentation here.
Related information
Visit the Technology and Pipeline pages of this website to learn about KMA.CAR-T